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Background: Congenital cytomegalovirus (cCMV) infection is the most common
infection acquired before birth and from which about 20% of infants develop permanent
neurodevelopmental effects regardless of presence or absence of symptoms at birth.
Viral escape from host immune control may be a mechanism of CMV transmission and
infant disease severity. We sought to identify and compare CMV epitopes recognized by
mother-infant pairs. We also hypothesized that if immune escape were occurring, then
one pattern of longitudinal CD8T cell responses restricted by shared HLA alleles would
be maternal loss (by viral escape) and infant gain (by viral reversion to wildtype) of CMV
epitope recognition.
Methods: The study population consisted of 6 women with primary CMV infection
during pregnancy and their infants with cCMV infection. CMV UL83 and UL123 peptides
with known or predicted restriction by maternal MHC class I alleles were identified, and
a subset was selected for testing based on several criteria. Maternal or infant cells were
stimulated with CMV peptides in the IFN-γ ELISpot assay.
Results: Overall, 14 of 25 (56%; 8 UL83 and 6 UL123) peptides recognized by
mother-infant pairs were not previously reported as CD8T cell epitopes. Of three pairs
with longitudinal samples, one showed maternal loss and infant gain of responses to a
CMV epitope restricted by a shared HLA allele.
Conclusions: CD8T cell responses to multiple novel CMV epitopes were identified,
particularly in infants. Moreover, the hypothesized pattern of CMV immune escape was
observed in one mother-infant pair. These findings emphasize that knowledge of paired
CMV epitope recognition allows exploration of viral immune escape that may operate
within the maternal-fetal system. Our work provides rationale for future studies of this
potential mechanism of CMV transmission during pregnancy or clinical outcomes of
infants with cCMV infection.
Keywords: cytomegalovirus, T cell, immune escape, epitope, congenital infection, mother-infant pairs,
immunology
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INTRODUCTION
Congenital cytomegalovirus (cCMV) infection is the most
common infection acquired before birth, with an incidence
of nearly 0.7% of live births in the United States (1). Of
all infected infants with or without CMV symptoms at birth,
almost 20% will develop permanent neurodevelopmental effects
such as sensorineural hearing loss, motor disability, cognitive
delay, or visual impairment (1). While current strategies to
prevent transmission consist of behavioral modifications during
pregnancy, there is no CMV vaccine or other intervention to
lower the risk of transmission from mother to fetus or reduce
severity of disease in affected infants. More effective prevention
and treatment strategies are needed, informed by a deeper
understanding of virus interaction with maternal and fetal hosts
during early congenital infection and of mechanisms underlying
CMV transmission.
Most studies of CMV-specific T cell responses have been
conducted in immunocompetent adults with chronic infection or
in solid organ or hematopoietic stem cell transplant recipients
with reactivation or donor-derived primary infection (2–5).
CMV UL83 (pp65) and UL123 (IE1) are known immunogenic
proteins in these populations and have been used as antigens to
study T cell responses in infants with cCMV infection (6–11).
CMV-specific CD8T cells have been detected in fetuses as early
as 22–28 weeks gestation (6, 8, 12), and were characterized by
oligoclonal expansion and late differentiation phenotype similar
to adults (6, 8). While these responses can increase in frequency
and breadth of CMV antigen recognition over time (8), their
function may be suboptimal (10, 13).
While these studies have provided essential details
characterizing CMV immunity in infants, none have examined
the dynamic interface between CMV and host immunity within
the maternal-fetal system as represented by mother-infant pairs.
An example of host-pathogen dynamics is immune escape,
whereby an organism thwarts the ongoing host innate or
adaptive immune response or “pressure” via genomic mutations
that diminish the efficacy of recognition. For viruses, such
mutations likely take the form of non-synonymous changes in
amino acid residues within or flankingMHC binding sites, which
in turn cause modified proteolysis, disruption of the epitope, and
ultimately lack of optimal T cell recognition.
CD8T cell escape has been reported for several RNA viruses in
adults, including HIV and hepatitis C and D viruses, particularly
during early acute infection (14–18). Some studies have examined
viral immune escape in congenital infection, primarily HIV (19–
23). Of note, Sanchez-Marino et al. (20, 24) showed that maternal
viral escape populations can be transmitted to the fetus, variant
amino acid sequences incur viral fitness cost, and infant HIV-
specific CD8T cells can exert selective pressure on subsequent
viral evolution. They also showed that the fate of transmitted
escape populations depends on mother-infant concordance for
MHC class I alleles restricting relevant CD8T cell responses:
mutations persist and allow continued viral escape in infants with
Abbreviations: HLA, human leukocyte antigen; MHC, major histocompatibility
complex.
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shared alleles, while fitness-cost mutations revert to wild type in
those with non-shared alleles. Previous studies have suggested
that CMV populations may be as diverse as RNA viruses (25,
26), raising the possibility that CMV genomic variants can
bypass protective maternal immunity, transmit to the fetus, and
influence severity of disease.
We conducted a pilot study to compare CMV epitope-specific
CD8T cell responses in women with primary CMV infection
during pregnancy and their infants with congenital CMV
infection. The goals of the study were to identify T cell response
signatures consistent with viral immune escape and to provide
new information about CMV-specific T cell peptide recognition
at early stages of CMV infection. We hypothesized that responses
restricted by shared HLA alleles would show maternal loss (by




Pairs of mothers with primary CMV infection during pregnancy
and their infants with cCMV infection (n = 6) were enrolled at
Fondazione IRCCS Policlinico SanMatteo in Pavia, Italy.Written
informed consent was obtained from adult participants and from
parents of infants. Characteristics of the subject population are
shown in Table 1.
Maternal primary CMV infection was determined by recent
CMV-specific IgG seroconversion, presence of CMV-specific
IgM and low IgG avidity, and/or presence of CMV nucleic acid
detection by PCR amplification. Timing of fetal infection was not
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known. cCMV infection was diagnosed by urine PCR at birth.
Five infants were asymptomatic at birth, and one (infant 129)
had chorioretinitis that subsequently resolved. All infants were
asymptomatic at the final follow-up visit (median 3 years, range
2–6 years).
Samples for the study consisted of non-antigen-specifically
expanded and viably cryo-preserved maternal CD8T cells
(PBMC were not available) and infant peripheral blood
mononuclear cells (PBMC). Maternal CD8T cell lines were
generated by incubating PBMCs in R10 medium with bi-specific
anti-CD3, 4b (final 2.5 mg/mL) (8, 27) and stimulating with
irradiated allogeneic PBMCs and anti-CD3 every 2–3 weeks for
a maximum of 6 weeks, then were cryopreserved (8, 27). Cell
lines were >80% CD8+ as determined by flow cytometry. Infant
PBMCs were cryopreserved directly.
CMV Peptides
CMVUL83/pp65 (n= 16) and UL123/IE1 (n= 12) 9- to 11-mer
peptides predicted to bind known maternal MHC class I alleles
were selected for testing based on previous studies, Immune
Epitope Database and Analysis Resource (IEDB) percentile rank,
BIMAS, and SYFPEITHI binding affinity scores in prediction
algorithms, and number of cell available for study. Peptides at
>95% purity were obtained from New England Peptide Inc.
(Gardner, MA). Lack of sufficient cells precluded confirming
HLA restriction of epitopes using targets expressing or matched
at single HLA alleles.
IFN-γ ELISpot Assay
The ELISpot assay was used to measure CMV peptide-specific
IFN-γ release (Human IFN-γ ELIspot Ready-SET-Go! from
FisherScientific, Cambridge MA). Samples from mother-infant
pairs were thawed simultaneously and stimulated with the same
peptides in concurrent assays.
Wells of 96 well flat-bottom plates (Millipore, Bedford MA)
were washed initially with 35% ethanol in sterile water, then 3
times with PBS without allowing the membranes to dry. Diluted
(1:250) capture antibody (100 µl) was added to each well and
plates were stored overnight at 4◦C. Wells were then washed
twice with 200 µl DPBS, blocked with T cell medium, and
incubated at 37◦C for 15 min.
Cells samples were thawed in a 37◦C water bath, washed
with medium spun at 1,500 rpm, counted, and diluted to 1 ×
106 cells/ml. A total of 105 cells were incubated with 0.5 µg of
peptide (final 10.0µg/mL) in each well. Mother and infant plates
were prepared simultaneously. Each timepoint had at least two
technical replicates, and included positive (≥2 wells of cells with
PHA 50 µl at 1 mg/mL; Gibco/Life Technologies), and negative
(≥4 wells of cells in medium only) (4) controls, except mother
125 at timepoint 170 days (Table 3B, Figure 1E) that did not
have a separate negative control. Plates were incubated at 37◦C
for 24 h.
After 24 h, plates were washed with DPBS and then DPBS
with Tween immediately prior to addition of biotinylated mAb
(1:250) (FisherScientific, Cambridge MA) then incubated for
2 h. Avidin peroxidase (1:250) (FisherScientific, Cambridge MA)
was added and plates were incubated for 1 h. Finally, plates
were washed, peroxidase substrate (FisherScientific, Cambridge
MA) was added, and the reaction was stopped after no more
than 15min. Spots were counted using a CTL Immunospot
plate reader.
HLA Typing of Infants
MHC class I alleles were known for mothers at the start of
the study. Using an aliquot of cells obtained at the time of
thawing for the ELISpot assay, BLCLs infants were generated
from EBV-transformed PBMCs grown in enriched RPMI 1640
media (FisherScientific, Cambridge MA) (28). Infant MHC
class I alleles were determined from BLCLs using a PCR-based
method (University of Massachusetts Tissue Typing Laboratory,
Worcester, MA).
Data Analysis
Epitope recognition patterns for CMV-specific CD8T cells
restricted by shared and non-shared HLA alleles were compared
between mothers and infants. Number of spots per million cells
was calculated. Responses >2 standard deviations above the
negative control were considered significant (7, 8, 29).
RESULTS
Novel CMV Peptides Elicited T Cell
Responses in Mothers and Infants
Predicted to be CMV epitopes based on maternal HLA alleles, a
total of 28 UL83 (pp65) or UL123 (IE1) peptides were tested for
CD8T cell responses in 6 mother-infant pairs, of which 25 (89%)
elicited detectable responses in the overall cohort (Table 2).
Of the 25 peptides, 21 (84%) were recognized by mothers with
primary CMV infection during pregnancy: 3 (14%) novel and 18
(86%) previously reported in adults. The 3 novel peptides were
identified in 2 B18 mothers: B18-NEIH-UL83 and B18-DEEL-
UL123 for mother 124 (and her infant), and B18-NEIH-UL83
and B18-TEEK-UL123 in mother 127 (although B18-DEEL-
UL123 could not be tested due to insufficient cells).
Similarly, of the 25 peptides, 17 (68%) were recognized by
infants with cCMV infection: 13 (76%; 8 UL83 and 5 UL123)
novel and 4 (24%; 2 UL83 and 2 UL123) previously reported in
infants (8).
For the overall cohort of mother-infant pairs, 14 of 25 (56%)
recognized peptides were not previously reported as CD8T cell
epitopes: 11 in infants only, 1 in a mother only (B18-TEEK-
UL123), and 2 in both groups (B18-DEEL-UL123 and B18-
NEIH-UL83).
CMV Peptide Recognition Pattern
Consistent With CMV Immune Escape
Longitudinal samples were available for 3 of 6 mother-infant
pairs. Of these three, pair 124 showed a CD8T cell recognition
pattern against shared-HLA B18-restricted CMV peptide NEIH-
UL83 consistent with the hypothesized viral escape model of
CMV transmission (Table 3A, Figure 1A).
Mother 124 responded to this peptide at 13 but not 45 days
after onset of primary CMV infection. In contrast, infant 124 did
not respond to this peptide at 1 day or 3.5 months of age, but the
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FIGURE 1 | (A–F) CMV peptide-specific responses in mother-infant pairs. IFN-γ secreting cells are expressed as spots per million PBMC (infants) or T cells (mothers).
Asterisk indicates significant response. Clear bars indicate negative control for each time point. UL83 (no box) or UL123 (box) peptides (first 4 amino acids in
sequence) with HLA restricting alleles. Infant 125 and mother 128 with no detectable responses are not shown.
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TABLE 2 | CMV peptides tested for T cell responses in 6 mother-infant pairs.
HLA CMV Amino acid Mother Infant Novel Novel
restriction protein sequence (adults) (infants)




























Shaded boxes, CMV-specific response detected in at least one mother or infant in
the cohort. X, novel peptides not previously reported as CD8T cell epitopes in adults
or infants.
response was detected at 26months of age. This maternal loss and
infant gain of response to a CMV epitope restricted by a shared
HLA allele would be expected with viral immune escape and
reversion to wildtype, respectively. A model of this viral escape
pattern is outlined (Figure 2).
Patterns of UL83- or UL123-Specific T Cell
Responses Among Individual Subjects and
Mother-Infant Pairs
Infant CMV-Specific Peptide Responses Not
Predicted by HLA Type
Two infants showed peptide-specific T cell responses that were
not expected based on their HLA types. Infant 127 was HLA-
A02, -A25, -B15, and -B37, but only responded to a B18-restricted
peptide (B18-DEEE-UL123) at 15 months of age and did not
respond to the B37-restricted peptide at any timepoint (Table 3C,
Figure 1B). Similarly, infant 128 was HLA-A01, -A03, -B08,
and -B27, but responded to a B35-restricted peptide (B35-IPSI-
UL83) at 14.5 and 28 months of age (Table 3D). Notably, the
response was at a lower frequency compared to either B08- or
A01-restricted peptides (Figure 1F).
Longitudinal Gain of Peptide Responses
Mother 131 showed increased breadth of peptide recognition
over time. At 83 days after onset of CMV infection, responses to 4
peptides (A02-NLVP-UL83, A02-RLLQ-UL83, B13-TRAT-UL83,
and A02-VLEE-UL123 were detected. By 186 days, the response
had expanded to include 3 additional peptides (A02-RIFA-UL83,
A02-TMYG-UL123, and B13-YILG-UL123) (Table 3F).
Infant 124 also showed expansion of peptide recognition.
At 1 day after birth, responses to 3 peptides (A11-GPIS-UL83,
A11-STHP-UL123, and B18-DELR-UL123) were detected. By 26
months, responses had expanded to 7 of the 8 peptides tested
(Table 3A).
Longitudinal Loss of Peptide Responses
Three infants (128, 129, and 131) and two mothers (124 and
131) showed loss of detectable responses to some peptides
while responses to others remained stable (Table 3, Figure 1).
Infant 128 had detectable responses to B35-IPSI-UL83 at 14.5
and 26 months of age, but loss of response to A03-KLGG-
UL123 over the same interval (Table 3D, Figure 1F). Infant 129
had loss of detectable responses to A02-MLNI-UL83 between
1 day and 6 months of age (Table 3E, Figure 1C). Infant 131
had the same pattern for A02-VLEE-UL123 and A02-NLVP-
UL83, respectively, at 3 days and 40 months of age (Table 3F,
Figure 1D). Mother 124 had sustained detectable responses to 4
of 8 peptides tested at 13 and 45 days after infection onset, but loss
of responses to B18-NEIH-UL83 and A11-STHP-UL123 over the
same interval (Table 3A). Mother 131 had detectable responses
to B13-TRAT-UL83 at all three timepoints sampled, but loss of
responses to A02-RLLQ-UL83 between 83 and 118 days after
infection onset (Table 3F).
DISCUSSION
We report results of a pilot study comparing CMV epitope-
specific CD8T cell responses in women with primary CMV
infection during pregnancy and their infants with congenital
infection. The goals of the study were to identify a hypothesized
pattern of T cell responses (maternal loss and infant gain)
consistent with viral immune escape and to describe CMV
peptide recognition in mother-infant pairs. We identified this
pattern in 1 of 3 mother-infant pairs with longitudinal samples
and defined novel CMV epitopes that elicited T cell responses
in the overall cohort. This work presents new information about
CMV-specific T cell peptide recognition at early stages of primary
or congenital infection in populations for whom previous studies
are limited. While CMV genome sequencing and therefore direct
evidence of viral mutation affecting T cell epitope recognition
was not possible, our results support further studies of immune
selection pressure on viral populations.
Several new CMV peptides were identified as targets of CD8T
cells, but the number differed between mothers and their infants:
Few (14%) of the maternal epitopes and most (81%) of the infant
epitopes had not been reported previously in adults with chronic
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TABLE 3 | (A) Longitudinal CD8T cell peptide recognition in pair 124 sharing HLA-A*11 and -B*18. (B–F) Longitudinal CD8T cell peptide recognition in pairs 125, 127,
128, 129, 131.
Loss (gray wedges) and gain (black wedges) of T cell responses as indicated.+, significant response detected in IFN-γ ELISpot assay (see Figure 1 for quantitative data). –, no response
detected; ND, not done due to insufficient cells available.
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FIGURE 2 | (A,B) Hypothesized pattern of viral escape and reversion to wild type (WT) in pair 124. CD8T cell responses to the HLA-B18-restricted CMV epitope
NEIH. (A) Viral mutation (or “escape”) in the presence of maternal CD8T cell response to wild type epitope resulting in loss of anti-WT response. (B) Viral reversion to
WT in the absence of fetal CD8T cell response to mutant epitope resulting in gain of anti-WT response.
or infants with cCMV infection, respectively. Of note, the 3 novel
maternal epitopes were B18-restricted, one of which (B18-NEIH-
UL83) elicited a detectable response in both HLA-B18 women in
the cohort. In line with previous studies (6, 8) responses to CMV
peptides were detected very early after birth.
As a primary mediator of immune protection, the interface
between T cells and viral epitopes within the maternal-fetal
system is an essential but inadequately understood aspect of
CMV pathogenesis. Few studies have examined CMV-specific
CD8T cells in adults with primary or infants with congenital
CMV infection, although some (10, 13, 30, 31) have noted
differences in responses between primary and chronic infection
and between infants and adults. CD8 but not CD4T cell
responses are similar in young children and adults during
congenital or primary CMV infection (31) suggesting that
stimulation of CD8T cells is a key feature of immune protection
at this early phase. Moreover, the role of CD8T cells in
controlling and monitoring as a biomarker for CMV reactivation
has been described in diverse patient populations (32–35). As
a result, CMV peptides that induce CD8T cell responses have
been used inmultiple CMV vaccine and adoptive T cell platforms
(36, 37), for which young children may be an optimal target
(38). A broad repertoire of protective CMV epitopes that elicit T
cell responses depending on phase of infection, age, or immune
function will facilitate the design of a CMV vaccine or other
immune-based interventions.
Our study also revealed differential patterns of CD8T
cell responses to CMV peptides over time in mother-infant
pairs. While this range of patterns may be in part due
to technical issues such as limitations in epitope prediction
models, maternal samples with differential expansion of maternal
CMV-specific T cells (despite non-specific stimulation in vitro) or
insufficient antigen-presenting cells, or low cell viability (unlikely
when responses to other peptides were detected at the same
timepoints), our experimental approach sought to minimize
these effects by preparing cells and performing ELISpot assays
for each mother and her infant simultaneously. Alternatively,
responses detected for the first time at a later timepoint may have
been present earlier but were undetectable by the ELISpot assay.
An increase in the number of CMV peptides recognized over
time was observed in pairs 124 and 131 for infant and mother,
respectively. Gibson et al. similarly demonstrated broadening of
peptide targeting in infants with cCMV infection, primarily to
UL123 (IE1) (8). Possible explanations for widening antigenic
breadth of CD8T cells over time include exposure to CMV
proteins during reactivation or persistent replication in tissue
compartments, CMV re-infection, CMV genome mutation and
altered amino acid sequences, or expansion of CMV-specific
CD4T cells and helper function (9, 31, 39–42).
In contrast, loss of CD8T cell responses to a single CMV
peptide was observed for each of infants 128, 129, and 131,
and mothers 124 and 131. A potential factor is CD8T cell
exhaustion associated with high antigen exposure, characterized
by a progressive loss of effector functions, increased expression of
inhibitory receptors such as PD-1, and inability to transition into
memory, and described in many chronic infections including
HIV, HCV, EBV, and CMV (13, 43, 44). Moreover, T cell
exhaustion has been shown to develop within 30 days after
infection in several animal and human viral infections (45–47).
While examining PD-1 and other markers of exhaustion was not
feasible, the infants in our cohort were likely CMV-infected long
enough for exhaustion to develop. Loss of single CMV peptide
recognition could also be attributed to viral escape from infant
CD8T cell selective pressure as described for congenital HIV
infection (20, 24). In these studies, HIV epitopes with single
amino acid substitutions were identified in infants during the
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first year of life but not in maternal plasma and reverted to wild
type coincident with loss of CD8T cell response, suggesting that
immune pressure in the infant led to their generation. Our study
is the first to report loss of CMV peptide recognition consistent
with this process in infants with cCMV infection.
Two infants in the cohort (127 and 128) had detectable
CD8T cell responses to CMV peptides (DEEE-UL123 and IPSI-
UL83, respectively) not predicted to bind their MHC class I
alleles, which was not observed in mothers since peptides were
chosen in part based on predicted binding. Of note, neither
peptide had been previously reported as a CD8T cell epitope
in infants. DEEE-UL123 is restricted by HLA-A01 (3) and has a
high binding affinity score for HLA-B18, but infant 127 does not
express either of these alleles. B35-IPSI-UL83 is included in the
QuantiFERON R©-CMV assay (Qiagen) used to monitor CMV-
specific CD8T cells in transplant recipients (2), but infant 128
does not express the restricting HLA allele B35.
This discrepancy between HLA restriction and detected T
cell response could be explained by MHC promiscuity and/or
limitations of epitope prediction models. While uncommon
(compared to CD4T cells) due to the restrictive size of the
MHC class I binding site (48), promiscuous binding of CD8T
cell epitopes by MHC class I molecules has been described (49).
At least half of HIV or EBV epitopes elicit a T cell response
in subjects lacking the reported restricting HLA allele (49, 50).
Similarly, EBV and CMV epitopes can be presented by the same
MHC class I molecule (51). MHC class I molecules can be
grouped into MHC supertypes based on similarities in binding
pocket characteristics (52). For example, MHC class I subtypes
B18 and B37 belong to the B44 supertype in which the B pocket
binds acidic residues and the F pocket binds aromatic, aliphatic,
and hydrophobic residues (52), and therefore could present the
same peptide. The potential for presentation by multiple HLA
alleles benefits CMV interventions based on T cell stimulation
with subsets of CMV peptides and use across diverse target
populations (36, 37).
A pattern of epitope recognition that may support our
hypothesis of viral escape and reversion was observed in mother-
infant pair 124 with concordance at the HLA restricting allele.
Maternal peptide B18 NEIH-specific CD8T cells were detected at
13 days but not at 45 days after onset of primary infection, which
would be predicted for viral immune escape. In contrast, peptide
B18 NIEH-specific CD8T cells were not identified in her infant
until 26 months of life, as would be expected for viral reversion
to wild type over time. While the possible explanations discussed
above for loss or gain of detectable responses may apply to this
individual mother or infant, the overall pattern for the pair is
consistent with viral escape and reversion.
As noted, several previous studies examining viral immune
escape in congenital (primarily HIV) infection (19–23), have
shown that CMV populations can be as diverse as RNA viruses
(26, 39, 53, 54), and identified signatures of positive selection
within individuals (55). These findings suggest that CMV can
escape the selective pressure of maternal immunity, and that
genomic variants can be transmitted to the fetus. If maternal viral
escape populations are transmitted, otherwise protective early
fetal responses for which the restricting MHC class I allele is
shared may be inadequate as virus continues to escape the new
fetal host immune system. In contrast, if the relevant restricting
allele is not shared, then uncompensated fitness-cost escape
mutations revert to wild type against which early fetal responses
are protective. This potential mechanism renders the HLA-
concordant fetus/infant at higher risk of severe or progressive
disease when virus escapes both maternal and fetal immune
control via mutations in critical protective epitopes, thus could
at least partially explaining the variability of disease severity
observed in infants with cCMV infection.
In summary, we have characterized several novel CD8T
cell CMV epitopes and illustrated a pattern of CMV immune
escape in one mother-infant pair that may operate within
the maternal-fetal system. Moreover, our study emphasizes
that CMV escape could impact not only transmission during
pregnancy and/or infant clinical outcomes, but also efficacy
of proposed treatment or prevention strategies. More detailed
examination of mother-infant pairs is needed to investigate host
immune selection and viral escape as a relevant mechanism
in congenital CMV transmission and severity, for which the
reported novel CD8T cell epitopes recognized by mother-
infant pairs may be useful. While appropriate samples were
not available for this study, CMV genome sequencing will be
necessary to identify polymorphisms that lead to epitope amino
acid substitutions and altered T cell binding. Our work provides
rationale for the planning and implementation of these studies.
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